Treatments cut risk of new brain metastases

The use of bevacizumab and immune checkpoint inhibitors can each reduce the risk of new brain metastases by about 30%, according to findings from new meta-analyses presented at SNO 2020.

Researchers from Penn State Health and Penn State Hershey Medical Center, in Hershey, Pennsylvania, and from the University of Texas Southwestern, in Dallas, USA, performed a systematic literature review for data published between January 2000 and June 2020, to drive two analyses.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.